SuRE™ promoter screening: customizing your therapy for improved safety and efficacy 

standing the challenge: the right place, the right time 

The development of cell and gene therapies is a complex and time-consuming process that depends on therapeutic genes being expressed in the right tissues, at the right time and at the right dosage. A key challenge lies in identifying and optimizing promoters and enhancers that precisely control transgene expression in target cells and which do not get silenced over time as seen for example for viral promoters. Conventional methods to generate novel promoters by rational design lacks throughput in both design and subsequent validation and novel computational design approaches still need to address the challenge of high-throughput real-life validation. 

Improving gene therapy and cell therapy with SuRE™ 

Annogen’s SuRE™ (Survey of Regulatory Elements) platform is a massively parallel reporter assay designed to expedite the discovery and optimization of gene promoters and enhancers critical for the success of cell and gene therapies. By providing a comprehensive solution for identifying, characterizing, and engineering optimal promoters, SuRE™ empowers researchers to develop safer, more effective, and durable therapeutic products. 

Key features of the SuRE™ platform include: 

    • High-throughput screening: Identify promoters through an unbiased, exhaustive in vitro screening of the entire human genome, followed by a large-scale screen of pairwise combinations of putative candidate sequences.   
    • In vivo compatibility: SuRE™ is compatible with a broad range of vectors, including plasmids, AAV, lentivirus, Sleeping Beauty, and PiggyBac, enabling screening in various cell types and conditions, both in vitro and in vivo.
    • Exclusive rights: Novel promoters identified in a bespoke screening program can be patented by the customer, providing you with a competitive advantage. 

Applications in cell and gene therapy 

SuRE™ has a broad range of applications in cell and gene therapy development, including:  

    • De novo promoter discovery
    • Promoter optimization
    • Inducible promoters
    • RNA structure and stability optimization 

Accelerate your development with Annogen 

Our team of experts is dedicated to supporting your research and development efforts, as we have done for numerous top biopharmaceutical companies before. We offer a range of services, including custom promoter identification and optimization, licensing opportunities for our proprietary promoters, as well as custom identification of favorable transgene integration sites.

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2

VectorY Therapeutics has received clearance from the U.S. FDA to begin its PIONEER-ALS Phase 1/2 Trial for VTx-002. This is a special type of antibody therapy designed to fight the root cause of most ALS cases: a faulty protein called TDP-43 . The VTx-002 treatment uses a harmless virus (AAV5.2 capsid) to deliver instructions to the body’s cells, turning them into tiny factories that continuously produce the therapeutic antibody. This allows the treatment to keep working after just one dose. A key piece of the instruction manual that ensures this continuous production is the promoter, which acts like an “on” switch for the antibody gene, and this vital component was developed by Annogen. The study will test the safety of VTx-002, which is designed to clean up toxic TDP-43 and help sick motor neurons recover.

Annogen Heads to London for the Advanced Therapies Congress 2026

Annogen Heads to London for the Advanced Therapies Congress 2026

Annogen today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use in certain pre-clinical hematopoietic stem cell (HSC) gene therapy programs.

Technology

 

Solutions

 

Annogen